These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7711362)

  • 21. World Hypertension Day 2007.
    Jones DW; Hall JE
    Hypertension; 2007 May; 49(5):939-40. PubMed ID: 17420339
    [No Abstract]   [Full Text] [Related]  

  • 22. Lipids and cardiovascular risk reduction -- new targets, new challenges.
    Jackson G
    Int J Clin Pract; 2005 Jun; 59(6):617-8. PubMed ID: 15924585
    [No Abstract]   [Full Text] [Related]  

  • 23. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
    MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of Centenarians.
    Baralla A; Sotgiu E; Deiana M; Pasella S; Pinna S; Mannu A; Canu E; Sotgiu G; Ganau A; Zinellu A; Sotgia S; Carru C; Deiana L
    PLoS One; 2015; 10(6):e0128029. PubMed ID: 26076476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. More about cardiovascular disease and lipid management in New Zealand.
    Metcalfe S; Moodie P
    N Z Med J; 2002 Oct; 115(1163):U203. PubMed ID: 12552309
    [No Abstract]   [Full Text] [Related]  

  • 26. [Focus on Cardiovascular prevention].
    Di Pasquale G
    G Ital Cardiol (Rome); 2017; 18(7):531-532. PubMed ID: 28714994
    [No Abstract]   [Full Text] [Related]  

  • 27. [Metabolic syndrome in men of 35-65 years old from rural district of Poltava region and possibility of the prophylactic therapy with atorvastatine].
    Kaĭdashev IP; Vasil'ev VN; Gorbas' IM; Petrushov AV; Rasin MS; Rasin AM; Smirnova IP; Iakimishina LI
    Lik Sprava; 2006 Dec; (8):48-52. PubMed ID: 17427425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Annual influenza immunization: as important as control of blood pressure and cholesterol as secondary prevention for cardiovascular disease.
    Grajewski J; Slusar M; Hayney MS
    J Am Pharm Assoc (2003); 2007; 47(5):662-3. PubMed ID: 17848356
    [No Abstract]   [Full Text] [Related]  

  • 30. The evolution of European guidelines: changing the management of cholesterol levels.
    Erhardt LR; Gotto A
    Atherosclerosis; 2006 Mar; 185(1):12-20. PubMed ID: 16309687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
    Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
    Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rheological blood behavior is not only influenced by cardiovascular risk factors but also by aging itself. Research into 927 healthy Spanish Mediterranean subjects.
    Vayá A; Alis R; Romagnoli M; Pérez R; Bautista D; Alonso R; Laiz B
    Clin Hemorheol Microcirc; 2013 Jan; 54(3):287-96. PubMed ID: 23686090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of the change in the Framingham Risk Score calculator between the 2006 and 2009 Canadian lipid guidelines.
    Armstrong DW; Brouillard D; Matangi MF
    Can J Cardiol; 2011; 27(2):167-70. PubMed ID: 21459264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PROSPER trial.
    Mascitelli L; Pezzetta F;
    Lancet; 2003 Feb; 361(9355):427; author reply 428. PubMed ID: 12573394
    [No Abstract]   [Full Text] [Related]  

  • 35. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hypercholesterolemia as cardiovascular risk in hypertensive patients. Therapeutic implications: efficiency of statins].
    Borghi C; Veronesi M
    Recenti Prog Med; 2003 Oct; 94(10):421-6. PubMed ID: 14619187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia.
    Gorkin JU; Watson K; Knopp RH
    J Fam Pract; 2007 Aug; 56(8 Suppl Strategies):S1-7; quiz S8. PubMed ID: 18667138
    [No Abstract]   [Full Text] [Related]  

  • 38. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No.
    Kendrick M
    BMJ; 2007 May; 334(7601):983. PubMed ID: 17494018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial: collecting new external evidence for cholesterol management.
    Streja D
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):121-3. PubMed ID: 26863279
    [No Abstract]   [Full Text] [Related]  

  • 40. Hypocholesterolaemic and antioxidant effects of yerba mate (Ilex paraguariensis) in high-cholesterol fed rats.
    Bravo L; Mateos R; Sarriá B; Baeza G; Lecumberri E; Ramos S; Goya L
    Fitoterapia; 2014 Jan; 92():219-29. PubMed ID: 24291756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.